SkinBioTherapeutics commercially launches psoriasis supplement

Skin health-focussed life sciences company SkinBioTherapeutics announced the commercial launch of ‘AxisBiotix-Ps’ on Friday, which it described as a probiotic food supplement to help alleviate the symptoms of psoriasis.

The AIM-traded firm said the launch followed the “highly positive” results from its consumer study, which ended in May.

As it had previously announced, commercialisation was starting on Friday in the UK and the United States markets.

SkinBioTherapeutics said AxisBiotix-Ps would be sold primarily on a subscription basis, and was priced per sachet, including VAT and excluding shipping and any duty costs, at $2.00 in the US, at £1.50 in the UK, and at €1.80 in the European Union in due course.

As demonstrated in the consumer study, it could take three to four weeks for the benefits of AxisBiotix-Ps to be achieved.

As a result, for an initial period, customers would receive 28 free sachets with their first purchase, with the product being sold in boxes containing 28 sachets, and customers able to subscribe on a four-weekly or eight-weekly basis.

In May, SkinBioTherapeutics reported on the outcomes of the study for participants that self-identified as suffering from psoriasis.

The results were “very positive”, and provided definitive support for the commercial development of AxisBiotix-Ps as a probiotic food supplement to help alleviate the symptoms of psoriasis.

Of participants that completed the study, 76% reported a reduction in itchiness and 73% reported that their skin felt less irritable.

“The launch of our first commercial product is a momentous occasion for SkinBioTherapeutics,” said chief executive officer Stuart Ashman.

“The interest in AxisBiotix-Ps, and overwhelmingly positive response from participants, has been hugely encouraging.

“We're delighted to introduce our product to the market on the most important of days for the global psoriasis community, as planned.”

Ashman said that since the “exciting results” from the consumer study, announced in May, the firm had seen a growing interest in the product.

“We have been working hard ever since to establish a reliable supply chain to ensure a continuous supply to all our customers upon launch.”

At 1107 BST, shares in SkinBioTherapeutics were down 6.27% at 70.3p.